Home Business Novo Nordisk shares stoop as weight-loss drug trial information disappoints – Financial...

Novo Nordisk shares stoop as weight-loss drug trial information disappoints – Financial Times

0


  1. Novo Nordisk shares stoop as weight-loss drug trial information disappoints  Financial Times
  2. Novo Nordisk shares plunge 22% after CagriSema weight problems drug trial outcomes  CNBC
  3. Novo Nordisk’s next-gen weight problems drug CagriSema achieves decrease weight reduction than anticipated  Reuters.com
  4. Novo Nordisk Stock Crashes 22% After Disappointing Obesity Drug Data. Eli Lilly Shares Soar.  Barron’s
  5. Novo Nordisk’s Shares Tank After Experimental Obesity Shot Misses Target  The Wall Street Journal

NO COMMENTS

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Exit mobile version